Large-scale chromatin immunoprecipitation with promoter sequence microarray analysis of the interaction of the nss protein of rift valley fever virus with regulatory dna regions of the host genome

Journal of Virology

Volumn 86, Issue 20, 2012, Pages 11333-11344

  Benferhat, Rima ^a   Josse, Thibaut ^b   Albaud, Benoit ^c   Gentien, David ^c   Mansuroglu, Zeyni ^b   Marcato, Vasco ^b   Souès, Sylvie ^b   Le Bonniec, Bernard ^d   Bouloy, Michèle ^a   Bonnefoy, Eliette ^b  

^a INSTITUT PASTEUR   (France)

^b CNRS   (France)

^c INSTITUT CURIE   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; PROTEIN NSS; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; BLOOD CLOTTING DISORDER; CELL ADHESION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC CODE; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA INTERACTION; PROTEIN MICROARRAY; REGULATORY DNA SEQUENCE; RIFT VALLEY FEVER BUNYAVIRUS; TRANSCRIPTION REGULATION; VIRUS GENOME;

ANIMALS; BLOOD COAGULATION FACTORS; CERCOPITHECUS AETHIOPS; CHROMATIN IMMUNOPRECIPITATION; DNA; GENOME-WIDE ASSOCIATION STUDY; HOST-PATHOGEN INTERACTIONS; INTERFERON-BETA; PROMOTER REGIONS, GENETIC; PROTEIN ARRAY ANALYSIS; REGULATORY SEQUENCES, NUCLEIC ACID; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; VERO CELLS; VIRAL NONSTRUCTURAL PROTEINS;

BOS; OVIS ARIES; PHLEBOVIRUS; RIFT VALLEY FEVER VIRUS;

EID: 84869056391     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01549-12     Document Type: Article

References (48)

1. Affar el B, et al. 2006. Essential dosage-dependent functions of the transcription factor Yin Yang 1 in late embryonic development and cell cycle progression. Mol. Cell. Biol. 26:3565-3581.
2. Bhalla SS, Robitaille L, Nemer M. 2001. Cooperative activation by GATA-4 and YY1 of the cardiac B-type natriuretic peptide promoter. J. Biol. Chem. 276:11439-11445.
3. Bouloy M, Flick R. 2009. Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines. Antiviral Res. 84:101-118.
4. Chang TH, et al. 2009. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog. 5:e1000493. doi:10.1371/journal.ppat.1000493.
5. Cheng C, Sharp PA. 2003. RNA polymerase II accumulation in the promoter-proximal region of the dihydrofolate reductase and _-actin genes. Mol. Cell. Biol. 23:1961-1967.
6. Coetzer JA. 1982. The pathology of Rift Valley fever. II. Lesions occurring in field cases in adult cattle, calves, and aborted foetuses. Onderstepoort J. Vet. Res. 49:11-17.
7. Delvaeye M, Conway EM. 2009. Coagulation and innate immune responses: can we view them separately? Blood 114:2367-2374.
8. Dungu B, et al. 2010. Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep. Vaccine 28:4581-4587.
9. Habjan M, et al. 2009. NSs protein of Rift Valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. J. Virol. 83:4365-4375.
10. Hensley LE, Geisbert TW. 2005. The contribution of the endothelium to the development of coagulation disorders that characterize Ebola hemorrhagic fever in primates. Thromb. Haemost. 94:254-261.
11. Huang NE, Lin CH, Lin Y, Yu WC. 2003. Modulation of YY1 activity by SAP30. Biochem. Biophys. Res. Commun. 306:267-275.
12. Huang SH, et al. 2011. JIP3 mediates TrkB axonal anterograde transport and enhances BDNF signaling by directly bridging TrkB with kinesin-1. J. Neurosci. 31:10602-10614.
13. Hung HL, et al. 2001. Regulation of human coagulation factor X gene expression by GATA-4 and the Sp family of transcription factors. Blood 97:946-951.
14. Ikegami T, et al. 2009. Dual functions of Rift Valley fever virus NSs protein: inhibition of host mRNA transcription and post-transcriptional downregulation of protein kinase PKR. Ann. N. Y. Acad. Sci. 1171:E75- E85.
15. Ikegami T, Makino S. 2011. The pathogenesis of Rift Valley fever. Viruses 3:493-519.
16. Isaacson MK, Ploegh HL. 2009. Ubiquitination, ubiquitin-like modifiers, and deubiquitination in viral infection. Cell Host Microbe 5:559-570.
17. Jansen van Vuren P, Tiemessen CT, Paweska JT. 2011. Antinucleocapsid protein immune responses counteract pathogenic effects of Rift Valley fever virus infection in mice. PLoS One 6:e25027. doi:10.1371/ journal.pone.0025027.
18. Johnson WE, et al. 2006. Model-based analysis of tiling-arrays for ChIPchip. Proc. Natl. Acad. Sci. U. S. A. 103:12457-12462.
19. Kalveram B, Lihoradova O, Ikegami T. 2011. NSs protein of Rift Valley fever virus promotes posttranslational downregulation of the TFIIH subunit p62. J. Virol. 85:6234-6243.
20. Kotenko SV, et al. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4:69-77.
21. Lara E, Billecocq A, Leger P, Bouloy M. 2011. Characterization of wild-type and alternate transcription termination signals in the Rift Valley fever virus genome. J. Virol. 85:12134-12145.
22. Lau JF, Nusinzon I, Burakov D, Freedman LP, Horvath CM. 2003. Role of metazoan proteins in interferon-responsive transcription. Mol. Cell. Biol. 23:620-628.
23. Lejeune D, et al. 2002. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J. Biol. Chem. 277:33676-33682.
24. Le May N, et al. 2004. TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. Cell 116:541-550.
25. Le May N, et al. 2008. A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells. PLoS Pathog. 4:e13. doi:10.1371/ journal.ppat.0040013.
26. Léonard VHJ, Kohl A, Hart TJ, Elliott RM. 2006. Interaction of Bunyamwera orthobunyavirus NSs protein with Mediator protein MED8: a mechanism for inhibiting the interferon response. J. Virol. 80:9667-9675.
27. Mansuroglu Z, et al. 2010. Nonstructural NSs protein of Rift Valley fever virus interacts with pericentromeric DNA sequences of the host cell, inducing chromosome cohesion and segregation defects. J. Virol. 84:928-939.
28. Mayer M, Bercsényl K, Géczi K, Szabó G, Lele Z. 2010. Expression of two type II cadherins, Cdh12 and Cdh22 in the developing and adult mouse brain. Gene Expr. Patterns 10:351-360.
29. McElroy AK, Nichol ST. 2012. Rift Valley fever virus inhibits a proinflammatory response in experimentally infected human monocyte derived macrophages and a pro-inflammatory cytokine response may be associated with patient survival during natural infection. Virology 422:6-12.
30. Miura E, et al. 2006. Expression and distribution of JNK/SAPKassociated scaffold protein JSAP1 in developing and adult mouse brain. J. Neurochem. 97:1431-1446.
31. Mohamed M, et al. 2010. Epidemiologic and clinical aspects of a Rift Valley fever outbreak in humans in Tanzania, 2007. Am. J. Trop. Med. Hyg. 83:22-27.
32. Morishita H, Yagi T. 2007. Protocadherin family: diversity, structure, and function. Curr. Opin. Cell Biol. 19:584-592.
33. Murphy EC, Mörgelin M, Cooney JC, Frick IM. 2011. Interaction of Bacteroides fragilis and Bacteroides thetaiotaomicron with kallikreinkinin system. Microbiology 157:2094-2105.
34. Nichol ST. 2005. The Bunyaviridae, p 695-716. In Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA (ed), Virus taxonomy. Classification and nomenclature of viruses. Eighth report of the International Committee on Taxonomy of Viruses. Elsevier Academic Press, London, United Kingdom.
35. Pépin M, Bouloy M, Bird BH, Kemp A, Paweska J. 2010. Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet. Res. 41:61. doi: 10.1051/vetres/2010033.
36. Popova TG, et al. 2010. Reverse-phase phosphoproteome analysis of signalling pathways induced by Rift valley fever virus in human small airway epithelial cells. PLoS One 5:e13805. doi:10.1371/journal.pone.0013805.
37. Renauld J-C. 2003. Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat. Rev. 3:667-675.
38. Ruf W. 2004. Emerging roles of tissue factor in viral hemorrhagic fever. Trends Immunol. 25:461-464.
39. Rust NM, et al. 2012. Bradykinin enhances Sindbis virus infection in human brain microvascular endothelial cells. Virology 422:81-91.
40. Schug J, et al. 2005. Promoter features related to tissue specificity as measured by Shannon entropy. Genome Biol. 6:R33. doi:10.1186/gb-2005-6-4-r33.
41. Sheppard P, et al. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4:63-68.
42. Smith DR, et al. 2010. The pathogenesis of Rift Valley fever virus in the mouse model. Virology 407:256-267.
43. Sparrer KMJ, Pfaller CK, Conzelmann K-K. 2012. Measles virus C protein interferes with beta interferon transcription in the nucleus. J. Virol. 86:796-805.
44. Swanepoel R, Coetzer JAW. 2004. Rift Valley fever, p 1037-1070. In Coetzer J, Tustin R (ed), Infectious diseases of livestock, vol 2. Oxford University Press, Cape Town, South Africa.
45. Verbruggen P, Ruf M, Blakqori G, Ö verby AK, Heidemann M, Eick D, Weber F. 2011. Interferon antagonist NSs of La Crosse virus triggers a DNA damage response-like degradation of transcribing RNA polymerase II. J. Biol. Chem. 286:3681-3692.
46. von Teichman B, et al. 2011. Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves. Vaccine 29:5771-5777.
47. Woodruff RS, Sullenger B, Becker RC. 2011. The many faces of the contact pathway and their role in thrombosis. J. Thromb. Thrombolysis 32:9-20.
48. Yadani FZ, Khol A, Préhaud C, Billecocq A, Bouloy M. 1999. The carboxy-terminal acidic domain of Rift Valley fever virus NSs protein is essential for the formation of filamentous structures but not for the nuclear localization of the protein. J. Virol. 73:5018-5025.